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Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-
resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this
ﬁrst-in-class alpha-emitting radiopharmaceutical underlies its favorable safety proﬁle and low incidence of myelosuppression.
In the pivotal phase 3 ALpharadin in SYMptomatic Prostate CAncer Patients study, radium-223 reduced the risk of death
by 30% and prolonged time to ﬁrst symptomatic skeletal event by 5.8 months. This article summarizes current guidelines
and clinical studies that led to the approval of radium-223 as an overall survival therapy, and discusses the urologist’s
perspective on using radium-223 in clinical practice. UROLOGY 85: 717e724, 2015.  2015 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rostate cancer is the fourth leading cause of US
cancer deaths and the most common cancerPmanaged by urologists, with >233,000 new cases
estimated for 2014.1 On diagnosis, approximately 12% of
patients will have locally advanced disease, and 4% of
newly diagnosed patients will present with metastatic
disease.1 Although newly diagnosed localized disease may
be cured with interventional therapies, approximately
30% of patients develop recurrent disease and may
progress to castration-resistant prostate cancer
(CRPC).1,2 As the clinicians chieﬂy responsible for
diagnosing, treating, and monitoring prostate cancer pa-
tients, urologists are uniquely positioned to provide a
detailed discussion of therapeutic options and promote
shared decision making with patients regarding approved
CRPC treatment options.
Although CRPC treatment options with unique
mechanisms of action (MOAs) have burgeoned since
2010, the disease eventually evolves via selective pres-
sures, with clonal expansion of cells harboring resistance
mutations. Unfortunately, this contributes to the annual
prostate cancerespeciﬁc death rate of 30,000 for US
men,1 of which approximately 90% will have evidence of
bone metastasis.3 Bone metastases are a clinically signif-
icant cause of morbidity and mortality, often resulting in
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hcord compression; they may also require either radiation
or surgical intervention.4,5 Bone-metastatic CRPC
(mCRPC)eassociated events can cause functional
disability, reduced quality of life (QOL), further compli-
cations that may impact survival, and ultimately health
care cost escalations.4-6 Urologists dedicated to evaluating
and managing therapeutic options for patients with pro-
gressive CRPC must be knowledgeable of approved
therapies that can delay disease progression and prolong
survival, and they must proactively manage the relatively
ubiquitous metastatic skeletal disease and the associated
potential complications.
Radium-223 dichloride (radium-223) is a ﬁrst-in-class
alpha-emitting radiopharmaceutical approved for treating
CRPC patients with symptomatic bone metastases with no
known visceral metastatic disease.7 Clinicians caring for
patients with progressive CRPC should understand the
radium-223 MOA, its role in the treatment plan for
appropriate CRPC patients, and its administration, efﬁ-
cacy, and safety proﬁle. This review summarizes the phase
3 registration clinical trial results, approved radium-223
indications and administration, ongoing and planned
radium -223 studies, and, importantly, a urologic perspec-
tive on implementing radium-223 in clinical practice.
Current CRPC treatment guidelines and phase 1-3 clinical
studies of radium-223 for CRPC and symptomatic bone
metastases were reviewed and their implications for using
radium-223 from the urologist’s perspective considered.
OVERVIEW OF RADIUM-223
Mechanism of Action
Radium-223, an alpha-emitting radiopharmaceutical,
mimics calcium in forming complexes with the bone
mineral hydroxyapatite, which speciﬁcally targets bone
metastases.8,9 Radium-223 preferentially targets new bonettp://dx.doi.org/10.1016/j.urology.2014.11.031
0090-4295/15
717
Figure 1. Radium-223 mechanism of action.growth surrounding bone metastases while emitting alpha
particles within the tumor microenvironment. Whereas
beta particles generate primarily single-stranded deoxy-
ribonucleic acid breaks that may be overcome by cellular
repair mechanisms, alpha particles have high linear en-
ergy transfer with enhanced ability to induce lethal
double-stranded deoxyribonucleic acid breaks, thus elic-
iting greater cytotoxic effects on bone-metastatic tumor
sites.9,10 The relatively large particle size and high linear
energy transfer of alpha particles translates into a short
effective range of <100 mm (2-10 cell diameters)
compared with other radioisotopes11; therefore, radium-
223 is bone targeted with a relatively low impact
on myeloproliferative tissue, thereby minimizing
myelosuppression-associated adverse events (AEs)
compared with earlier generation bone-targeted radio-
pharmaceuticals that use beta and gamma isotopes
(Fig. 1).8,10
Early Radium-223 Clinical Studies
In both ﬁrst-in-human phase 1 trials in breast and pros-
tate cancer with documented skeletal metastases, single-
dose radium-223 was well tolerated at all therapeutically
relevant doses (46-250 kBq/kg intravenously [IV]), with
no dose-limiting hematologic toxicity and only mild and
transient myelosuppression (neutropenia, leukopenia, and
thrombocytopenia).12,13 In a follow-up, phase 1, dose-
escalation study in advanced prostate cancer with skel-
etal metastases, radium-223 was well tolerated to a total
dose of 250 kBq/kg.12,13
In subsequent phase 2 studies in CRPC patients with
symptomatic bone metastases, radium-223 was well
tolerated with a positive effect on pain assessments (Brief
Pain Inventory functional index; Table 1).14-16 Radium-
223 was associated with reduced serum markers of bone
turnover, including bone alkaline phosphatase, procolla-
gen I N propeptide, C-terminal cross-linking telopeptide
of type I collagen, and type I collagen cross-linked C-
telopeptide, suggesting a role for bone markers in better
understanding the radium-223 efﬁcacy signals.
Phase 3 ALSYMPCA Trial
The phase 3 ALpharadin in SYMptomatic Prostate
CAncer Patients (ALSYMPCA) trial was a randomized,
double-blind, placebo-controlled, multicenter, multina-
tional trial of patients with histologically conﬁrmed,
progressive CRPC with 2 bone metastases detected on
skeletal scintigraphy, no known visceral metastases, and
symptomatic disease.17 In ALSYMPCA, symptomatic
disease was deﬁned as regular use of opioid or nonopioid
analgesic medication or treatment with external beam
radiation therapy (EBRT) within the previous 12 weeks
for cancer-related bone pain. The primary end point was
overall survival (OS); key secondary end points included
time to ﬁrst symptomatic skeletal event (SSE), changes
in prostate-speciﬁc antigen (PSA) and alkaline phos-
phatase levels, safety, and QOL assessments. SSEs
comprised the need to administer EBRT for bone pain,718new symptomatic pathologic bone fracture (vertebral or
nonvertebral), spinal cord compression, and tumor-
related orthopedic surgical intervention. Morphometric
assessment for asymptomatic fractures was not performed
on a routine basis.
Patients were randomized 2:1 to receive 6 injections of
radium-223 (50 kBq/kg IV) or a saline placebo infusion; a
cycle comprised 1 injection every 4 weeks, and a
completed course consisted of 6 cycles. During the trial
evaluation, patients received the best standard of care
(BSOC) at the investigator’s discretion; this may have
included ketoconazole, glucocorticoids, antiandrogens,
estrogens, or focal palliative EBRT. A total of 921 pa-
tients were randomized: 614 to the experimental radium-
223 arm and 307 to the placebo arm; 43% had a World
Health Organization (WHO) ladder for cancer pain score
of 1 (mild pain, analgesic use, no opioid use), indicating
that a signiﬁcant proportion of ALSYMPCA patients
with symptomatic disease did not use opioids. Addition-
ally, 43% had no prior docetaxel therapy because of
investigator or patient preference; hence, this segment of
the trial population was chemotherapy naive.
In the ALSYMPCA trial, radium-223 treatment
resulted in a 30% reduction in risk of death among
radium-223 patients vs placebo. Median OS was
14.9 months with radium-223 and 11.3 months with
placebo (hazard ratio [HR] ¼ 0.70; 95% conﬁdence in-
terval [CI], 0.58-0.83). Additionally, radium-223 vs pla-
cebo signiﬁcantly prolonged median times to ﬁrst SSE
(15.6 vs 9.8 months; HR ¼ 0.66; 95% CI, 0.52-0.83;
P <.001).17,18 Radium-223 was associated with an overall
low incidence of grade 3 or 4 myelosuppression (throm-
bocytopenia, 6% vs 2% placebo; neutropenia, 2% vs 1%;
and anemia, 13% vs 13%) and a low incidence of grade 3
or 4 gastrointestinal AEs (diarrhea, 2% vs 2% placebo;
vomiting, 2% vs 2%; and constipation, 1% vs 1%).17
Radium-223 had a beneﬁcial effect on delaying pain19
and preserving health-related QOL,17 with time to EBRTUROLOGY 85 (4), 2015
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UROLOGY 85 (4), 2015for bone pain being signiﬁcantly longer for radium-223
than for placebo (HR ¼ 0.67; 95% CI, 0.53-0.85) and
median time to initial opioid use being signiﬁcantly
longer for radium-223 than for placebo (HR ¼ 0.62; 95%
CI, 0.46-0.85).18,19 Finally, a signiﬁcantly higher per-
centage of radium-223 than placebo patients had a clin-
ically meaningful improvement in health-related QOL
based on the Functional Assessment of Cancer Ther-
apyeProstate score (increased 10 points from the
baseline) over the drug administration period (25% vs
16%; P ¼ .02).17
Ongoing and Future Studies
A number of radium-223 clinical trials (www.clinicaltrials.
gov) are ongoing. In ALSYMPCA, 574 (62%) patients
have entered a 3-year follow-up (radium-223, n ¼ 406;
placebo, n ¼ 168),20 evaluating the occurrence of
treatment-related AEs, including acute myelogenous leu-
kemia, myelodysplastic syndrome, aplastic anemia, primary
bone cancer, and primary cancer in other organs. At 1.5-
year post-treatment follow-up, 322 (79%) radium-223 pa-
tients and 145 (86%) placebo patients have withdrawn
from the study, primarily because of death. During this
period, 37 treatment-related AEs were reported in 25 of
404 (6%) radium-223 patients and 8 of 167 (5%) placebo
patients; primary cancers in other organs occurred in 5
patients (2 radium-223 and 3 placebo patients). Myelo-
suppression incidence among radium-223 patients
was 3%, with no reports of acute myelogenous leukemia,
myelodysplastic syndrome, or primary bone cancer.20
Lowmyelosuppression rates and uniqueMOA of radium-
223 have raised interest in combining radium-223 with
other agents. A phase 2 trial investigating its combination
with abiraterone or enzalutamide (NCT02034552) and
a phase 3 trial with abiraterone and prednisone
(NCT02043678) are ongoing. Additional radium-223
clinical trials include a phase 1 or 2 study evaluating safety
and efﬁcacy of radium-223 plus docetaxel in CRPC patients
with symptomatic bone metastases (NCT01106352).
Although the phase 2 segment is ongoing, phase 1 showed
noAE-related radium-223discontinuations or delays andno
long-term toxicity during the 3-month follow-up, which
began when the study treatment ended.21
A phase 1 or 2 study evaluating safety of retreatment
with 6 additional doses is under way (NCT01934790).
The short radium-223 half-life (11.4 days) and low
myelosuppression rates during treatment permit adminis-
tration of multiple doses at relatively short (4 week) in-
tervals. Multiple doses may improve the radiation dose
homogeneity, a factor likely to contribute to OS
beneﬁt.13 Early-access programs in CRPC patients with
symptomatic bone metastases are assessing radium-223
acute and long-term safety, within and outside of the
United States (NCT01516762 and NCT01618370).
Future studies will explore radium-223 efﬁcacy and safety
in treating breast cancer (NCT01070485), osteosarcoma
(NCT01833520), and other cancers associated with bone
metastases.719
Figure 2. Radium-223 within the metastatic castration-resistant prostate cancer treatment paradigm.7 Treatment paradigm
based on Food and Drug Administrationeapproved indication of each agent. *For patients with symptomatic bone metas-
tases. Solid bars, approved with overall survival beneﬁt; striped bar, no overall survival beneﬁt. Distance is not proportional to
time. EBRT, external beam radiation therapy; mCRPC, metastatic castration-resistant prostate cancer. (Color version is
available online.)Radium-223 Handling and Administration
Radium-223 is generally administered by radiation on-
cologists or nuclear medicine physicians certiﬁed to
handle radioisotopes by their state Nuclear Regulatory
Commission. It is provided as a ready-to-use solution for
slow bolus IV injection >45-60 seconds, with a shielding
container and decay correction table.22 The currently
recommended and Food and Drug Administration
(FDA)eapproved regimen is 6 doses of radium-223 50
kBq (1.35 mCi) IV per kilogram of body weight, admin-
istered at 4-week intervals. Radium-223 reaches its target
rapidly after IV administration, with w60% of injected
activity taken up by the bone within 4 hours.22
Alpha particles emitted by radium-223 are relatively
large and easily shielded by skin. However, radium-223
should be handled and administered by trained personnel,
taking appropriate radiation safety precautions to reduce or
eliminate exposure risk.22 Radium-223 decays into a stable
product and has to be discarded as fecal waste following
standard universal precautions.22 Given the potential for
bone marrow suppression (albeit lower than that with other
radioisotopes approved for pain palliation of bone metas-
tases), complete blood counts are taken before each
radium-223 administration, and treatment discontinued
with sustained bone marrow suppression. Before initial
radium-223 administration, the hemoglobin, platelet, and
absolute neutrophil counts should be 10 g/dL, 100 
109/L, and 1.5  109/L, respectively, and hematologic
evaluation should precede every subsequent dose.22 Sub-
sequent radium-223 administrations require an absolute
neutrophil count of 1  109/L and a platelet count
of 50  109/L.22 Concomitant radium-223 with chemo-
therapy is not recommended (outside a clinical trial)
because of potential additive effects on bone marrow.22
UROLOGIST’S PERSPECTIVE
Radium-223 in the CRPC Treatment Paradigm
Radium-223 and several other approved agents prolong-
ing OS in phase 3 trials have recently been incorporated720with traditional palliative therapies into CRPC treatment
guidelines (Fig. 2; Table 2).7,11,23 Sipuleucel-T is an
autologous immunotherapy, administered IV, and rec-
ommended for asymptomatic or minimally symptomatic
mCRPC patients.7 Cabazitaxel, an IV-administered
cytotoxic chemotherapy, is recommended as an option
for patients previously treated with docetaxel who have
demonstrated disease progression.7,11,23 Abiraterone ace-
tate, an androgen biosynthesis inhibitor orally adminis-
tered in combination with prednisone, is a treatment
option for patients with asymptomatic or minimally
symptomatic mCRPC, both before and after docetaxel
chemotheraphy.7 Enzalutamide, an orally administered
androgen-receptor signaling inhibitor, is also an approved
option for CRPC patients in the prechemotherapy and
postchemotherapy settings.11,24
Radium-223, an IV-administered option for patients
with CRPC with symptomatic bone metastases, may be
considered either before or after docetaxel therapy.25 In
the ALSYMPCA trial, 57% of patients had received prior
docetaxel therapy, whereas 43% had not (due to ineligi-
bility or patient refusal).17 Efﬁcacy and safety in both
populations were subsequently analyzed; radium-223 pro-
longed OS vs placebo, irrespective of prior docetaxel use.
In patients with no prior docetaxel, median OS was
16.1 months with radium-223 vs 11.5 months with pla-
cebo (HR ¼ 0.75; 95% CI, 0.56-0.99; P ¼ .039); in pa-
tients with prior docetaxel, median OS was 14.4 months
with radium-223 vs 11.3 months with placebo (HR ¼
0.71; 95% CI, 0.57-0.89; P ¼ .003).25 The incidence of
myelosuppression was low in both subgroups; however,
patients with prior docetaxel had a signiﬁcantly higher
incidence of grade 3 or 4 thrombocytopenia with radium-
223 vs placebo (9% vs 3%, respectively; P ¼ .01).25
In the ALSYMPCA trial, both radium-223 and the
placebo control-arm patients were allowed concomitant
BSOC at the time of the trial enrollment (eg, local
EBRT, glucocorticoids, antiandrogens, ketoconazole, or
estrogens)17; the options were equally distributed between
the 2 treatment arms. Since its availability as part of anUROLOGY 85 (4), 2015
Table 2. AUA recommended CRPC therapeutic options*
Therapy Mechanism of Action
AUA Recommended
Clinical Casesy Administration Pros Cons
Radium-223 Alpha-emitting
radiopharmaceutical
Index patient 3-5 Slow IV injection Improvement in OS and delay
time to SSE
Mild diarrhea, very low risk of
myelosuppression
Strontium-89,
samarium-153
Beta-emitting
radiopharmaceutical
Index patient 3-4, 6 Slow IV injection Pain palliation Myelosuppression, no OS beneﬁt
Flutamide, bicalutamide,
nilutamide
First-generation antiandrogen Index patient 1-2 Oral Modest PSA beneﬁt No published OS beneﬁt
Ketoconazole þ steroid First-generation androgen
synthesis inhibitor
Index patient 1-6 Oral PSA beneﬁt No published OS beneﬁt, nausea,
hepatotoxicity
Abiraterone acetate þ
prednisone
Androgen synthesis inhibitor Index patient 2-6 Oral Improvement in OS and
radiographic progression-free
survival
Mineralocorticoid-related adverse
events, hepatotoxicity
Enzalutamide Androgen receptor antagonist Index patient 5-6 Oral Improved OS, PSA beneﬁt,
progression-free survival,
time to ﬁrst SRE, and quality
of life
Fatigue, diarrhea, hot ﬂashes,
seizure
Sipuleucel-T Immunotherapy Index patient 2 IV infusion Improvement in OS No PSA beneﬁt
Mitoxantrone Antineoplastic,
anthracenedione
Index patient 3-4 IV infusion Pain palliation No improvement in OS vs
docetaxel
Docetaxel Antineoplastic, taxane Index patient 2-5 IV infusion Improvement in OS, pain palliation Severe side effect proﬁle
Cabazitaxel Index patient 5 IV infusion Improvement in OS, and
progression-free survival
Diarrhea, hematologic toxicity
(neutropenia)
AUA, American Urological Association; OS, overall survival; PSA, prostate-speciﬁc antigen; SRE, skeletal-related event; SSE, symptomatic skeletal event; other abbreviations as in Table 1.
* Taken from 2014 Update of the AUA Guideline for castration-resistant prostate cancer.
y Index patient proﬁles: 1, asymptomatic nonmetastatic CRPC; 2, asymptomatic or minimally symptomatic, metastatic CRPC without prior docetaxel chemotherapy; 3, symptomatic, metastatic CRPC
with good performance status and no prior docetaxel chemotherapy; 4, symptomatic, metastatic CRPC with poor performance status and no prior docetaxel chemotherapy; 5, symptomatic, metastatic
CRPC with good performance status and prior docetaxel chemotherapy; and 6, symptomatic, metastatic CRPC with poor performance status and prior docetaxel chemotherapy.
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Early Access Program after FDA approval on May 15,
2013, in this author’s experience, the majority of radium-
223 patients will receive a concomitant novel oral hor-
monal antiandrogen as well as an androgen deprivation
therapy. Safety and tolerability of concomitant radium-
223 with these newer agents (abiraterone acetate and
enzalutamide) are being further evaluated in the Early
Access Program and ongoing trials. Combinatorial stra-
tegies involving radium-223 may further broaden future
potential mCRPC treatment options for patients, both
before and after docetaxel chemotherapy. As we have
progressed from paucity to plethora of CRPC agents that
demonstrate a survival beneﬁt in phase 3 trials, their
optimal sequence and combinatorial strategies for treating
mCRPC are evolving.7,23,26 Given its unique MOA and
favorable safety proﬁle, radium-223 has the potential to
be successfully combined with hormonal, chemothera-
peutic, and immunologic options for mCRPC patients.
The National Comprehensive Cancer Network (NCCN)
guidelines recommend radium-223 as a ﬁrst-line treat-
ment option, both before docetaxel chemotherapy and as
a postdocetaxel treatment option in CRPC patients with
symptomatic bone metastases (category 1).7 Importantly,
as of May 2014, the American Urological Association
(AUA) CRPC guidelines now also recommend radium-
223 as a standard treatment option both before and af-
ter docetaxel chemotherapy in CRPC patients with
symptomatic bone metastases (Table 2).7,26,27Patient Selection
Urologists should have a deﬁning role in the early iden-
tiﬁcation of CRPC patients and subsequently in their
careful evaluation for all approved mCRPC therapies
including radium-223; thus, they should have timely
discussions with patients regarding the most suitable and
preferred treatment options, based on the published data
and recent NCCN and AUA guidelines. Given the
expanding and aging male population, as well as the
lengthening survival of CRPC patients, there is ongoing
interest in maintaining the QOL metrics throughout the
course of CRPC disease progression. This discussion is
increasingly common in urologic practices caring for
advanced prostate cancer patients. Urologists evaluating
and managing mCRPC patients should be well versed in
their comprehension of the level-1 evidence within the
peer-reviewed literature, as well as the AUA and NCCN
guideline recommendations for mCRPC patients. Inter-
estingly, the recently updated AUA guideline deﬁnes
“symptomatic” more narrowly than the ALSYMPCA
inclusion criteria. The currently approved mCRPC
treatment options improve OS via distinct MOAs, and a
given therapeutic may also have speciﬁc and unique side
effects. In the absence of unforeseen accessibility or
ﬁnancial considerations, it should become increasingly
more likely that a mCRPC patient will receive most, if
not all, of these CRPC therapies as he progresses through
his disease course (Table 2); this emphasizes the722importance of further establishing the ideal sequencing
and combinatorial strategy for the individual patient.
Appropriate radium-223 candidates may have mini-
mally symptomatic or symptomatic mCRPC (requiring
nonopioid or opioid analgesic medications), no lymph
nodes >3 cm in diameter, and no concomitant visceral
metastases. In the ALSYMPCA trial, 42% and 45% of
radium-223 and placebo patients, respectively, had a
WHO ladder for cancer pain score of 1 (requiring non-
opioid analgesic medications), and 56% and 55%,
respectively, had a baseline WHO ladder score of 2 or 3
(requiring opioid analgesic medications).14 Radium-223
may be administered with no required preadministration
or postadministration medications; there is no food
requirement other than an enhanced hydration recom-
mendation, and there has been a demonstrated low inci-
dence of severe AEs (Table 2).17 Radium-223 has been
combined with other traditional nonchemotherapeutic
antineoplastic agents as demonstrated with the concomi-
tant BSOC administration in the ALSYMPCA trial. Even
though there are no FDA-labeled contraindications for its
use with denosumab, abiraterone acetate and prednisone,
or enzalutamide, these combinatorial strategies and their
associated safety proﬁles are still under investigation.
Radium-223 may be considered both before and after
docetaxel chemotherapy.28Patient Monitoring and Education
Urologists should have a pivotal role in the monitoring
and treatment selection for their CRPC patients. The
careful monitoring of patients transitioning from non-
metastatic to asymptomatic mCRPC will identify patients
who may beneﬁt from approved CRPC therapies that can
extend OS. Unfortunately, most mCRPC patients will
eventually develop bone-related symptomatology,
becoming appropriate candidates for a course of radium-
223. The ideal radium-223 patient selection will have
symptomatic bone metastases, yet no visceral metastases
or malignant lymphadenopathy exceeding 3 cm. As a
course of radium-223 therapy requires a 6-month interval
(each cycle is administered on an every 4-week basis),
there should be a careful evaluation and consideration of
the potential timing of future chemotherapy administra-
tion. Concomitant administration of a novel oral
hormonal agent, as discussed earlier, remains under
investigation. Serum biomarkers are often used to
monitor CRPC treatment efﬁcacy; the Prostate-Cancer
Working Group (PCWG2) recommends basing the de-
cision to discontinue treatment on clinical symptom-
atology and therapeutic tolerability, as well as
radiographic progression, not solely on PSA kinetics.29
Docetaxel, abiraterone acetate, and enzalutamide may
be associated with a PSA response, as their MOAs will
impact the androgen receptor and subsequent PSA gene
transcription. Other approved CRPC therapies with
alternative MOAs not directly inﬂuencing the androgen
receptor, such as sipuleucel-T, radium-223, zoledronicUROLOGY 85 (4), 2015
acid, and denosumab, are much less likely to signiﬁcantly
affect PSA kinetics.23,30,31
As radium-223 is a ﬁrst-in-class alpha-emitting radio-
pharmaceutical with a unique MOA distinguishing it
from beta-emitting radiopharmaceuticals, patients and
caregivers require education regarding radium-223 efﬁ-
cacy and safety. Urologists should communicate that
although radium-223 provides relief of bone pain in some
patients, pain palliation should not be used as a marker
for efﬁcacy, as pain palliation was not a primary end point
in the ALSYMPCA trial.17 Clinicians should plan for the
patient to receive all 6 cycles of radium-223, which is the
recommended treatment course to achieve OS beneﬁt.22
Therefore, patient disease volume and performance status
relating to all CRPC options should be considered. On
choosing a course of radium-223 therapy, patients will
require a complete blood count within 1 week before
each administration to establish acceptable hematologic
status; fecal matter and other body waste should be
handled with standard universal precautions.22 There are
no patient restrictions regarding nonsexual contact with
caregivers and others after a radium-223 treatment.
Radium-223: A Multidisciplinary Therapy
Urologists, in solo practice or as part of a multidisciplinary
team, can now offer CRPC patients another treatment
option in addition to immunotherapy, novel hormonal
agents, and cytotoxic chemotherapies. With a dedicated
and comprehensive understanding of these agents’ efﬁ-
cacy and safety, urologists can effectively manage
advanced prostate cancer, collaborate with other spe-
cialists, and educate patients to make informed decisions
in a timely and beneﬁcial manner during their CRPC
course of care.
Urologists may work in tandem with medical oncolo-
gists and radiation oncologists to discuss with patients the
advantages and disadvantages of an oral hormonal ther-
apy, chemotherapy, immunotherapy, or radiopharma-
ceutical. If radium-223 therapy is initiated, urologists can
coordinate the administration with a nuclear medicine
radiologist or a radiation oncologist while monitoring
patients during and after the therapeutic course.
CONCLUSION
For urologists dedicated to CRPC patient care, radium-
223 is an important therapeutic option for treating pa-
tients with symptomatic bone metastases. Radium-223
prolongs OS, delays time to ﬁrst SSE, and is associated
with a beneﬁcial effect on pain and QOL.17 The safety
proﬁle has been established, speciﬁcally demonstrating a
low incidence of myelosuppression (3%).20,22
Current challenges to the successful incorporation of
radium-223 into the CRPC treatment paradigm include
the timing of sequential and combination therapy with
other approved CRPC options. Although radium-223
provides pain palliation in some patients, this is not a
surrogate measure for efﬁcacy and should not promptUROLOGY 85 (4), 2015discontinuation in the absence of an analgesic effect. Once
initiated, the full 6-cycle radium-223 course should be
administered to potentiate the survival beneﬁt. In the
ALSYMPCA trial, radium-223 was administered along
with the BSOC at each center; however, its role in com-
bination therapy with other newly approved CRPC ther-
apies has not yet been established. Future and ongoing
studies will explore the combination of radium-223 with
currently available CRPC agents. Finally, as radium-223
becomes incorporated into the CRPC treatment discus-
sion, logistic workﬂow can be established to facilitate
interdisciplinary treatment among medical oncology, ra-
diation oncology, nuclear medicine, and urology clinics.
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